BURST-AF, a 101-patient first-in-human study of Argá Medtech’s Coherent Sine-Burst Electroporation platform, reported 100% procedural success and 94% overall lesion durability with 60–90-day remapping. Pulmonary vein isolation durability reached 97.4% in paroxysmal and 91.7% in persistent AF; cavo-tricuspid isthmus lines were 100% and 97.4% durable, respectively. Posterior wall isolation durability in persistent AF was 92.1% inferior and 84.2% superior. At 6 months, freedom from AF/AFL/AT was 96.6% in paroxysmal and 92.1% in persistent patients (with or without AAD). At 12 months off AAD, rates were 90.9% and 82.4%. No PV stenosis, silent cerebral events, coronary spasm, phrenic injury, esophageal injury, or conduction disorders were reported.
The core development is twofold: a strong first-in-human signal across multiple lesion sets using a single, stylet-driven, multi-configurable catheter, and rapid enrollment progress in the company’s U.S. IDE pivotal, COHERENT-AF, which has reached 50% of its planned up-to-360-patient cohort across U.S. and European sites. Procedural efficiency was notable, with reported ablation times of roughly 20 minutes for PVI and an additional 15 minutes for linear lesions. The platform’s sine-burst waveform and energy titration for tissue depth, delivered through a shape-shifting catheter capable of circular, linear, or focal lesions, target a long-standing operational friction point: catheter exchanges that add time, cost, and air embolism risk.
Strategically, the emphasis on durability beyond PVI is a direct response to current PFA realities. Balloon-centric systems have reset safety expectations, but persistent AF outcomes remain constrained by inconsistent creation of complex lesion sets and variable durability on remapping. By foregrounding remapped durability for posterior wall and CTI lines, Argá is positioning its platform not just as another PFA entrant but as a tool for substrate modification approaches that many operators still pursue in persistent AF. The single-catheter architecture is also an explicit workflow play aimed at reducing inventory complexity and room time, potentially shifting purchasing calculus from balloon disposables toward a versatile, lab-wide tool.
For sites and operators, the operational promise is fewer exchanges, shorter ablation time, and flexibility to address non-PVI lesions without swapping hardware. That can translate into higher throughput and simpler staffing patterns, though real-world gains will hinge on mapping integration, catheter handling, and the learning curve. For CROs and sponsors working in electrophysiology, the rapid IDE enrollment underscores strong investigator pull for platforms that tackle non-PVI lesion durability; it also signals that remapping-centric designs are gaining currency as endpoints mature beyond 12‑month freedom alone. Regulators will scrutinize durability and collateral safety across broader operator profiles, particularly esophageal and neurologic signals, where PFA has set high expectations but requires consistent documentation.
Next, all eyes move to the full COHERENT-AF readout: persistent AF performance, durability at 12 months beyond early remap signals, and reproducibility across a larger, more heterogeneous operator base. The absence of a randomized comparator in the IDE will keep cross-platform comparisons informal; any move toward head-to-heads or robust historical control bridging will shape adoption narratives in labs already committed to existing PFA generators. Capital placement and service models, integration with mapping systems, and training pathways will influence speed of uptake as much as clinical data. Watch for whether the single-catheter approach can sustain procedure times and durability in routine practice, how posterior wall safety holds under broader use, and whether Argá can convert enrollment momentum into an on-time PMA with a manufacturing and support footprint ready for scale in an increasingly consolidated EP market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
